UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Managing wtATTR: Standard of Care and New Directions

Key Information
summary/abstract

The standard of care for wild-type ATTR amyloidosis (wtATTR) centers on TTR stabilizers like tafamidis, which slow disease progression. Patients must carefully manage symptoms with diuretics and often need to avoid standard heart medications like beta-blockers that can worsen fatigue.

Treating wild-type transthyretin amyloidosis (wtATTR) has evolved from simply managing symptoms to using “disease-modifying” therapies that target the underlying protein problem. Because your heart is thick and stiff (restrictive), it responds differently to medications than a “typical” heart failure patient might